Scientific Articles

Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study

13 Dec 2022

Prof Paolo A Ascierto, Daniil Stroyakovskiy, Prof Helen Gogas,Prof Caroline Robert, Prof Karl Lewis, Svetlana Protsenko, Rodrigo P Pereira, Thomas Eigentler, Piotr Rutkowski, Lev Demidov, Natalia Zhukova, Prof Jacob Schachter,Yibing Yan, Ivor Caro, Christian Hertig, Cloris Xue, Lieke Kusters, Prof Grant A McArthur, Prof Ralf Gutzmer

The Lancet Oncology, Novembrer 29, 2022

Abstract link

Forse può anche interessarti

Privacy Overview
AIOM

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Analytics

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.